ACT-21 PRIMARY EXPERIENCE OF NOVOTTF THERAPY FOR THE PATIENTS WITH GBM IN OUR INSTITUTION

BACKGROUND: Based on EF-14 clinical trial, NovoTTF therapy prolong overall survival in the patients with GBM. However, NovoTTF treatment does not become standard therapy because treatment procedures are cumbersome and potentially impose psychological burden on patients who suffer from dismal disease. In our institution, we can choose NovoTTF therapy as one of the treatment options for GBM patients since June 2018. In this report, we summarized primary experience of this novel treatment. MATERIALS AND METHODS: Adult patients with primary GBM diagnosed after June 2018 were retrospectively reviewed. We investigated the suggestion of NovoTTF, patients’ acceptance, the reason of rejection of NovoTTF, and the condition of NovoTTF treatment. RESULTS: Among 22 GBM patients, 12 cases were proposed NovoTTF treatment in actual. In 10 cases who were not proposed NovoTTF, the reasons were 1) poor performance status (KPS 50% or less); 7 cases, oldest-old; 1 case, unavailable care person; 2 cases. In 12 cases who were proposed NovoTTF, 5 cases (42%) accepted and performed this therapy. Remaining 7 cases did not accept NovoTTF because rejection of shaving hair; 1 case, troublesome for daily work; 2 cases, refusal due to cumbersome procedure; 2 cases, unavailable cooperation with care person(s); 2 cases. 5 cases treated NovoTTF were 3 males and 2 females, and the median age was 67yo (range 25yo-69yo). All patients were continued NovoTTF for 1–7 months without major complication. In two cases, minor skin trouble was observed, but easy to handle by putting ointment.